Physician
Neurology
Dr. Michael C. Irizarry, MD
Michael Irizarry works in the field of Neurology. He went to Georgetown University School of Medicine. Georgetown University School of Medicine is ranked 49/84 in Research/PrimaryCare. Michael Irizarry is also a published MD. He has 92 publication published. The most recent publication is: Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
Publications
- Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.
- Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.
- Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.
- Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer''s disease: two phase 3 st...
- Modeling Alzheimer's disease progression using the disease system analysis approach.
- Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsy.
- Rosiglitazone monotherapy in mild-to-moderate Alzheimer''s disease: results from a randomized, double-blind, placebo-controlled phase III study.
- Genetic deficiency of plasma lipoprotein-associated phospholipase A2 (PLA2G7 V297F null mutation) and risk of Alzheimer''s disease in Japan.
- Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.
- Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
- Exploring differential prescribing between anti-epileptic drugs in epilepsy patients with a history of mood disorders.
- An exploration of cognitive subgroups in Alzheimer''s disease.
- Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials.
- Rapid progression from mild cognitive impairment to Alzheimer''s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 ...
- Performance characteristics of plasma amyloid-beta 40 and 42 assays.
- Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial.
- Plasma urate and progression of mild cognitive impairment.
- Serum cystatin C and the risk of Alzheimer disease in elderly men.
- Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study.
- Predictors of placebo group decline in the Alzheimer''s disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer''s disease.
- Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.
- Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.
- Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.
- Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study.
- The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer''s disease.
- Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains.
- Plasma F2A isoprostane levels in Alzheimer''s and Parkinson''s disease.
- Expression of APP pathway mRNAs and proteins in Alzheimer''s disease.
- Plasma Abeta levels do not reflect brain Abeta levels.
- Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
- Prospective study of plasma folate, vitamin B12, and cognitive function and decline.
- No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer''s disease brain.
- GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing.
- Prevalence and effects of lobar microhemorrhages in early-stage dementia.
- Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels.
- Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
- Relation of quantitative indexes of concurrent alpha-synuclein abnormalities to clinical outcome in autopsy-proven Alzheimer disease.
- Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.
- Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
- Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
- Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.
- The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.
- Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.
- Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy.
- Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation.
- Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer''s disease.
- Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein.
- Biomarkers of Alzheimer disease in plasma.
- Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.
- Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington''s disease age of onset.
- Beta-secretase activity increases with aging in human, monkey, and mouse brain.
- Genotyping of apolipoprotein E: comparative evaluation of different protocols.
- FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice.
- APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease ...
- Brain isoprostanes: a marker of lipid peroxidation and oxidative stress in AD.
- Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes.
- A turn of the sulfatide in Alzheimer's disease.
- Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
- Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
- Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels.
- Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease.
- Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease.
- LRP and senile plaques in Alzheimer''s disease: colocalization with apolipoprotein E and with activated astrocytes.
- Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice.
- Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies.
- Alzheimer disease therapeutics.
- Elevation of cystatin C in susceptible neurons in Alzheimer's disease.
- Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption.
- Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice.
- Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein.
- beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging.
- Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice.
- Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not assoc...
- Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.
- alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining.
- Clinical and neuropathological correlates of dementia with Lewy bodies.
- Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background.
- Clinical and quantitative pathologic correlates of dementia with Lewy bodies.
- Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice.
- Dynamics of plaque formation in Alzheimer's disease.
- Risperidone treatment of behavioral disturbances in outpatients with dementia.
- Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
- Stereology: a practical primer for neuropathology.
- Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.
- APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1.
- Delayed complications thirty-six years after hemispherectomy: a case report.
- Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system.
- Cocaine-associated cerebral vasculitis.
- Paresthesia as a side effect of the new antidepressant, nefazodone.
- Parasomnias as neuropsychiatric complications of electrical injury.
- The formation of strand breaks in DNA after high-LET irradiation: a comparison of data from in vitro and cellular systems.
Schools
Georgetown University
Mass Gen Hospital
Doctors Specialties
- Neurology
Accepted Insurances
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
Massachusetts General Hospital -
Georgetown University School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Cynthia K. McGarvey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann Marie M. Hake, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas L. King, MD |
|
|
Dr. David L. Steiman, MD |
|
Dr. Devin D. Mackay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah E. Zauber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward C. Daly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olaniyi O. Osuntokun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Travis J. Hassell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashley P. Ghiaseddin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Miller, MD |